Almotriptan

Drug #1704

Almotriptan is a selective serotonin (5-HT) agonist with actions similar to those of sumatriptan. Almotriptan is used for the management of migraine attacks.

← Previous drug Next drug →

Primary Characteristics

It is of Synthetic origin.

Molecular Weight: 469.56 · Solubility in Water: 1.21e-01mg/ml · Non-proprietary name: Almotriptan.

Pharmacokinetics

Absorption: Almotriptan has an oral bioavailability is 35% (±35%).

Distribution: Almotriptan has a volume of distribution is 180-200litres. plasma protein binding is 35%.

Elimination: plasma half-life is 3.5 hours, renal excretion is >75%.

Indications

Almotriptan is primarily indicated in conditions like Migraine.

Contraindications

Almotriptan is contraindicated in conditions like Peripheral vascular disease, Cerebrovascular accident, Uncontrolled hypertension, Severe hypertension associated with renal disease.

Dosage

Almotriptan's dosage details are as follows:

Dose	Single Dose	Frequency	Route	Instructions
Adult Dosage
6.25 mg/day	6.25 mg/day	—	PO	In patients with hepatic impairment the maximum daily dose should not exceed 12.5 mg over a 24-hour period.
9.375 mg/day	9.375 mg/day	—	PO	If the headache is relieved after the initial dose but returns, the dose may be repeated after 2 hours. The effectiveness of a second dose has not been established in placebo-controlled trials. The maximum daily dose should not exceed 25 mg. The safety of treating an average of more than four migraines in a 30-day period has not been established.
Paediatric Dosage (20kg)
No data.
Neonatal Dosage (3kg)
No data.

Drug Interactions

3 interactions

Always consult your physician for the change of dose regimen or an alternative drug of choice that may strictly be required.

Side Effects

Almotriptan is known to cause more or less tolerable side effects which are usually transient. These include Diarrhea, Dizziness, Drowsiness, Dry mouth, Dyspepsia , Dysuria, Fatigue, Flushing, Heaviness, Nausea and vomiting, Sensation of warmth, Tingling , Transient increase in blood pressure.

Warnings / Precautions

5HT1 agonists (e.g Almotriptan) should be used with caution in conditions which predispose to coronary artery disease (pre-existing cardiac disease), pregnancy and breast-feeding. 5HT1 agonist s are recommended as monotherapy and should not be taken concurrently with other acute migraine therapies. Little information is available on the use of these drugs in the elderly (over 65 year). Caution is also required in mild or moderate hepatic impairment; severe renal impairment; sensitivity to sulphonamides; not to be taken until 24 hours after stopping ergotamine-type prepration (ergotamine-type prepration not to be taken until 6 hours after Almotriptan)

Available Brands

None recorded.

Storage Conditions

Almotriptan should be stored tabs.

Drug Classification

1.7.1 — Acute migraine attack